Jeremy Springhorn
@SpringhornJ
CEO @nidobio . Opinions are my own and do not reflect my employer.
You might like
Proud to start as CEO of 4:59 Newco, a 5AM Ventures Company and looking forward to all the great things we will accomplish.
As #RareDiseaseDay2021 approaches - Great day for MOCD patients as #Nulibry is approved. Proud to have played even a small part in its journey
We are building a leading #hematology franchise w/ 2 clinical-stage drug candidates across 3 genomically defined patient populations w/ the potential to set new standards of care. #AML #MDS #APL ow.ly/upCB50DpoH5
Well said
2 died of Ebola: They said Obama should resign. 4 died in Benghazi: They had Hillary testify for 11 hours, held 33 hearings, and launched a multiyear probe. 248,585 died thanks to Trump’s malevolence: They cheer him on, and deny the reality that he lost to Biden by a landslide.
So funny - well played
2 died of Ebola: They said Obama should resign. 4 died in Benghazi: They had Hillary testify for 11 hours, held 33 hearings, and launched a multiyear probe. 248,585 died thanks to Trump’s malevolence: They cheer him on, and deny the reality that he lost to Biden by a landslide.
1. Board management and development experience. 2. Strong external relationships, especially pharma & investors. 3. Operating and business experience. 4. Spirit of partnership with CEO. 5. Gravitas w/ rest of board, especially investors.
What make a kick-ass chair, Michael? I've been curious about that
Looking forward to working with our new Partner - Global Blood Therapeutics on behalf of Sickle Cell Patients globenewswire.com/news-release/2…
Please for the sake of humanity, Let’s break twitter with the hashtag #WEAREBALTIMORE! Please let @realDonaldTrump see good beats evil every time!
Congratulations Feng Zhang @zhangf of @broadinstitute, newly inducted #NASmember! He developed CRISPR/Cas systems for genome editing and continues to discover and develop molecular technologies for improving human health. #NAS156 #CRISPR
We announced clinical data from our ongoing phase 2 trial of SY-1425 in genomically defined AML & MDS patients at #ASH2018 ir.syros.com/press-releases…
If you're at #ASH2018, come see us at our poster presentation from 6-8 pm PST this evening! We are poster number 2735.
Chugai spoiling #Alexion debut of ravulizumab. chugai-pharm.co.jp/english/news/d…
Good fun and great work at Syros. Consider joining us. biospace.com/article/syros-…
Founders of @ovarian101, Bob &Diane Riche & Seana Roubinek (center), a patient battling her 3rd recurrence, visited our team yesterday. We’re amazed by their shared commitment to education, advocacy & research in support of early detection & better therapies for ovarian cancer.
We're at it again! Last year, @NancyAnn14 reigned supreme at our #LabOlympics. Will she take the trophy home again tonight? Leadership and coaches ready! Funds raised during this event support @LLSusa . Donate to our #LightTheNight team today! pages.lightthenight.org/ma/BostonL18/S…
We presented new preclinical data on SY-1365 showing potent anti-tumor activity in multiple models of heavily pretreated ovarian cancer at the @AACR Annual Meeting in Chicago. More here: ir.syros.com/press-releases… #AACR2018
Interested in a new challenge? I am looking for a BD professional to join the team. Check it out at syros.com/careers/job/20…
Very happy to be joining such a talented team at @SyrosPharma with such a promising pipeline/platform
"Too often patients with rare diseases are forced to accept illness as the new normal. We can help" J. Springhorn, Road's End #2017GGSUMMIT
United States Trends
- 1. Jesse Jackson N/A
- 2. Good Tuesday N/A
- 3. #tellmelies N/A
- 4. RIP Rev N/A
- 5. Rev. Jackson N/A
- 6. #CatForCashEP5 N/A
- 7. Rest in Power N/A
- 8. The Rev N/A
- 9. Happy Lunar New Year N/A
- 10. Civil Rights Movement N/A
- 11. Bree N/A
- 12. Martin Luther King Jr. N/A
- 13. Stephen N/A
- 14. Pippa N/A
- 15. Lucy N/A
- 16. James Talarico N/A
- 17. #WWERaw N/A
- 18. Tyra N/A
- 19. Robert Dorgan N/A
- 20. Wrigley N/A
Something went wrong.
Something went wrong.